相关实验视频

Updated: Jan 18, 2026

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

困难的Clostridioides的减弱感染的Clostridiumhylemonae的感染

Sueun Choi¹, Heewon Kwon¹, Woon-Ki Kim^1,2

¹Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul 08826, Republic of Korea.

Journal of microbiology and biotechnology

|January 15, 2026

概括

用C.hylemonae (DSM 15053) 治疗困难菌感染 (CDI) 增加了肠道微生物的多样性. 这表明C.hylemonae可能有助于恢复因CDI和抗菌剂使用而破坏的肠道微生物群.

科学领域:

微生物学微生物学
胃肠病学胃肠病学
传染性疾病传染性疾病

背景情况:

困难肠杆菌感染 (CDI) 破坏了肠道微生物群,需要恢复肠道平衡的治疗.
抗菌剂的使用是CDI的主要风险因素,因为它削弱了殖民抵抗力.
识别有益于微生物群恢复的细菌对于管理CDI至关重要.

研究的目的:

在CDI的小鼠模型中评估Clostridium hylemonae DSM 15053的疗效.
调查C.hylemonae DSM 15053可能减轻CDI的机制.
为了比较C.hylemonae DSM 15053与Clostridium scindens的作用机制.

主要方法:

使用了一个Clostridioides difficile感染 (CDI) 的小鼠模型.
管理C.hylemonae DSM 15053并评估其对CDI的影响.
进行肠道微生物群分析,包括元基因组和代谢组概况.
评估的二次胆酸 (SBA) 生产.

主要成果:

治疗C.hylemonae DSM 15053并没有显著增加SBA产量.
微生物多样性和丰富性在C.hylemonae DSM 15053治疗组与对照组相比显著更高.
在C.hylemonae DSM 15053治疗后,Phocaeicola,Akkermansia和Parabacteroides属的丰富性增加了.
与C. scindens相比,C. hylemonae DSM 15053通过不同的机制减轻了CDI.

结论:

在CDI模型中,C. hylemonae DSM 15053增强了肠道微生物的多样性和丰富性.
通过C.hylemonae DSM 15053缓解CDI的机制不同于C.scindens.看到的胆酸调节.
C. hylemonae DSM 15053显示出作为一种治疗剂的潜力,可以在CDI后恢复肠道微生物群.

关键词:

7α-脱氧化脱氧化在C.hylemonae DSM 1505353中发现.艰难的闭膜炎感染 (CDI)便便便便便便微生物群移植便微生物群移植我们的肠道微生物群.二次胆汁酸二次胆汁酸二次胆汁酸

更多相关视频

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...